Lv4
626 积分 2021-05-08 加入
Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer
4小时前
已完结
Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial
4小时前
已完结
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
4小时前
已完结
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients
4小时前
已完结
Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?
4小时前
已完结
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study
4小时前
已完结
Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis
4小时前
已完结
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year study
4小时前
待确认
Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer
4小时前
已完结
Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
4小时前
已完结
皖公网安备34019202002308
